The antihyperlipidemic effects of coenzyme Q10 and gemfibrozil on hyperlipidemic male rats: a comparative study
Open Access
- 21 May 2024
- journal article
- research article
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (2) , 139-145
Abstract
Dyslipidemia is considered as the most common risk factor for cardiovascular diseases, cerebrovascular diseases, and fatty liver disease. The available therapy aimed to decrease lipid profile and reduced long-term risk which do require lifelong therapy, hence adverse effects are suggestive. The goal of the present study is to compare the anti¬hyperlipidemic influence and hepatic side effects of CoQ10 and gemfibrozil in the hyperlipidemic male rats model. Twenty-five albino rats were divided into 5 groups: group 1(normal group), group 2 (olive oil group), group 3(hyperlipidemia-induced group) group 4 (CoQ10-treated group), and group 5 (gemfibrozil-treated group). Induction of hyperlipidemia lasts for 90 days and treatment lasts for 30 days. Serum liver enzyme analysis and liver histological study conducted to demonstrate the safety profile of the treatment agents. Analysis of the data revealed that the lipid profile parameters (except HDL) and liver enzymes were significantly (p< 0.001) higher in the hyperlipidemic group (Group 3) compared to either the control group (Group 1) or olive oil group. Using CoQ10 (Group 4) and gemfibrozil (Group 5) has revealed that the lipid parameters and liver enzymes were significantly (p<0.001) lower compared to the hyperlipidemic group (Group 3). Compared to control group, liver showed congestion of sinusoids, severe necrosis of hepatocytes, vacuolar degradation, and infiltration of inflammatory cells, these effects reversed in presence of CoQ10. Compared to gemfibrozil, CoQ10 provides safer and equally effective option for treatment of dyslipidemia represented by improved lipid parameters and liver enzymes alongside protected hepatic architecture.Keywords
This publication has 34 references indexed in Scilit:
- The Role of Probiotics in Colorectal Cancer: A ReviewJournal of Gastrointestinal Cancer, 2023
- Rosuvastatin and co-enzyme Q10 improve high-fat and high-fructose diet-induced metabolic syndrome in rats via ameliorating inflammatory and oxidative burdenBiomedicine & Pharmacotherapy, 2022
- Enhanced antihyperlipidemic potential of gemfibrozil under co-administration with piperineCurrent Research in Pharmacology and Drug Discovery, 2021
- Synergistic anti-atherosclerotic role of combined treatment of omega-3 and co-enzyme Q10 in hypercholesterolemia-induced obese ratsHeliyon, 2020
- The impact of coenzyme Q10 on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trialsEndocrinology, Diabetes & Metabolism, 2020
- Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic ratsLife Sciences, 2018
- Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseedAtherosclerosis, 2005
- Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula retz. fruitJournal of Ethnopharmacology, 2002
- Effects of combined quercetin and coenzyme Q10 treatment on oxidative stress in normal and diabetic ratsJournal of Biochemical and Molecular Toxicology, 2002
- Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice A proposed model for drug screeningAtherosclerosis, 1988